William L Carroll

William L Carroll


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SBSamuel W. Brady
Samuel W. Brady
KRKathryn G. Roberts
Kathryn G. Roberts
ZGZhaohui Gu
Zhaohui Gu
LSLei Shi
Lei Shi
SPStanley Pounds
Stanley Pounds
CMCharles G Mullighan
Charles G Mullighan

3 February 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JMJulia A Meyer
Julia A Meyer
JWJinhua Wang
Jinhua Wang
LHLaura E Hogan
Laura E Hogan
JYJun Yang
Jun Yang
SDSmita Dandekar
Smita Dandekar
WCWilliam L Carroll
William L Carroll
William Carroll and colleagues report the identification of mutations in NT5C2, encoding cytosolic 5′-nucleotidase II, which are specific for relapsed childhood acute lymphoblastic leukemia. The mutations confer increased enzymatic activity and resistance to treatment with nucleoside analog therapies in vitro. Relapsed childhood acute lymphoblastic leukemia (ALL) carries a poor prognosis, despite intensive retreatment, owing to intrinsic drug resistance1,2. The biological pathways that mediate resistance are unknown. Here, we report the transcriptome profiles of matched diagnosis and relapse bone marrow specimens from ten individuals with pediatric B-lymphoblastic leukemia using RNA sequencing. Transcriptome sequencing identified 20 newly acquired, novel nonsynonymous mutations not present at initial diagnosis, with 2 individuals harboring relapse-specific mutations in the same gene, NT5C2, encoding a 5′-nucleotidase. Full-exon sequencing of NT5C2 was completed in 61 further relapse specimens, identifying additional mutations in 5 cases. Enzymatic analysis of mutant proteins showed that base substitutions conferred increased enzymatic activity and resistance to treatment with nucleoside analog therapies. Clinically, all individuals who harbored NT5C2 mutations relapsed early, within 36 months of initial diagnosis (P = 0.03). These results suggest that mutations in NT5C2 are associated with the outgrowth of drug-resistant clones in ALL.

28 May 2020 in Cancer Cell
Verified
Journal Article
Closed access
MWMatthew T. Witkowski
Matthew T. Witkowski
IDIgor Dolgalev
Igor Dolgalev
NENikki A. Evensen
Nikki A. Evensen
CMChao Ma
Chao Ma
TCTiffany Chambers
Tiffany Chambers
IAIannis Aifantis
Iannis Aifantis

21 January 2016 in ACS Chemical Biology
Verified
Journal Article
Closed access
RARachel P. Abrams
Rachel P. Abrams
WCWilliam L Carroll
William L Carroll
KWK. A. Woerpel
K. A. Woerpel

10 November 2011 in Blood
Verified
Journal Article
Open access
PDF file
LHLaura E. Hogan
Laura E. Hogan
JMJulia A. Meyer
Julia A. Meyer
JYJun Yang
Jun Yang
JWJinhua Wang
Jinhua Wang
NWNicholas Wong
Nicholas Wong
WCWilliam L Carroll
William L Carroll
Despite an increase in survival for children with acute lymphoblastic leukemia (ALL), the outcome after relapse is poor. To understand the genetic events that contribute to relapse and chemoresistance and identify novel targets of therapy, 3 high-throughput assays were used to identify genetic and epigenetic changes at relapse. Using matched diagnosis/relapse bone marrow samples from children with relapsed B-precursor ALL, we evaluated gene expression, copy number abnormalities (CNAs), and DNA methylation. Gene expression analysis revealed a signature of differentially expressed genes from diagnosis to relapse that is different for early (< 36 months) and late (≥ 36 months) relapse. CNA analysis discovered CNAs that were shared at diagnosis and relapse and others that were new lesions acquired at relapse. DNA methylation analysis found increased promoter methylation at relapse. There were many genetic alterations that evolved from diagnosis to relapse, and in some cases these genes had previously been associated with chemoresistance. Integration of the results from all 3 platforms identified genes of potential interest, including CDKN2A, COL6A2, PTPRO, and CSMD1. Although our results indicate that a diversity of genetic changes are seen at relapse, integration of gene expression, CNA, and methylation data suggest a possible convergence on the WNT and mitogen-activated protein kinase pathways.

15 November 2008 in Blood
Verified
Journal Article
Open access
PDF file
JYJun Yang
Jun Yang
DBDeepa Bhojwani
Deepa Bhojwani
WYWenjian Yang
Wenjian Yang
XCXiangjun Cai
Xiangjun Cai
GSGabriele Stocco
Gabriele Stocco
WCWilliam L Carroll
William L Carroll
The underlying pathways that lead to relapse in childhood acute lymphoblastic leukemia (ALL) are unknown. To comprehensively characterize the molecular evolution of relapsed childhood B-precursor ALL, we used human 500K single-nucleotide polymorphism arrays to identify somatic copy number alterations (CNAs) in 20 diagnosis/relapse pairs relative to germ line. We identified 758 CNAs, 66.4% of which were less than 1 Mb, and deletions outnumbered amplifications by approximately 2.5:1. Although CNAs persisting from diagnosis to relapse were observed in all 20 cases, 17 patients exhibited differential CNA patterns from diagnosis to relapse. Of the 396 CNAs observed in 20 relapse samples, only 69 (17.4%) were novel (absent in the matched diagnosis samples). EBF1 and IKZF1 deletions were particularly frequent in this relapsed ALL cohort (25.0% and 35.0%, respectively), suggesting their role in disease recurrence. In addition, we noted concordance in global gene expression and DNA copy number changes (P = 2.2 × 10−16). Finally, relapse-specific focal deletion of MSH6 and, consequently, reduced gene expression were found in 2 of 20 cases. In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse.